+

WO2005023995A3 - Composes oligomeres chimeriques comprenant des zones alternees a geometrie conformationnelle nord et sud - Google Patents

Composes oligomeres chimeriques comprenant des zones alternees a geometrie conformationnelle nord et sud Download PDF

Info

Publication number
WO2005023995A3
WO2005023995A3 PCT/US2004/029821 US2004029821W WO2005023995A3 WO 2005023995 A3 WO2005023995 A3 WO 2005023995A3 US 2004029821 W US2004029821 W US 2004029821W WO 2005023995 A3 WO2005023995 A3 WO 2005023995A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligomeric compounds
northern
southern
conformational geometry
alternating regions
Prior art date
Application number
PCT/US2004/029821
Other languages
English (en)
Other versions
WO2005023995A2 (fr
Inventor
Brett P Monia
Madeline M Butler
Robert Mckay
Brenda F Baker
Original Assignee
Isis Pharmaceuticals Inc
Brett P Monia
Madeline M Butler
Robert Mckay
Brenda F Baker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34278750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005023995(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isis Pharmaceuticals Inc, Brett P Monia, Madeline M Butler, Robert Mckay, Brenda F Baker filed Critical Isis Pharmaceuticals Inc
Priority to EP04788713.8A priority Critical patent/EP1670896B1/fr
Publication of WO2005023995A2 publication Critical patent/WO2005023995A2/fr
Publication of WO2005023995A3 publication Critical patent/WO2005023995A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne des nouveaux composés oligomères chimériques possédant plusieurs zones alternées comportant soit une géométrie conformationnelle de type ARN à 3'-endo ou nord (zones 3'-endo), soit une géométrie conformationnelle de type ADN C2'-endo/04'-endo ou sud. Les composés oligomères de cette invention entraînent une réduction des niveaux d'ARNm dans de multiples systèmes de dosage in vitro et in vivo et sont utiles, par exemple, dans le traitement et la recherche.
PCT/US2004/029821 2003-09-09 2004-09-09 Composes oligomeres chimeriques comprenant des zones alternees a geometrie conformationnelle nord et sud WO2005023995A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04788713.8A EP1670896B1 (fr) 2003-09-09 2004-09-09 Composes oligomeres chimeriques comprenant des zones alternees a geometrie conformationnelle nord et sud

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50171903P 2003-09-09 2003-09-09
US60/501,719 2003-09-09
US56848904P 2004-05-06 2004-05-06
US60/568,489 2004-05-06

Publications (2)

Publication Number Publication Date
WO2005023995A2 WO2005023995A2 (fr) 2005-03-17
WO2005023995A3 true WO2005023995A3 (fr) 2007-09-20

Family

ID=34278750

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/029821 WO2005023995A2 (fr) 2003-09-09 2004-09-09 Composes oligomeres chimeriques comprenant des zones alternees a geometrie conformationnelle nord et sud

Country Status (3)

Country Link
US (3) US20050074801A1 (fr)
EP (1) EP1670896B1 (fr)
WO (1) WO2005023995A2 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050233342A1 (en) * 2003-03-07 2005-10-20 Muthiah Manoharan Methods of preventing off-target gene silencing
US7399853B2 (en) * 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
US7750142B2 (en) * 2003-04-28 2010-07-06 Isis Pharmaceuticals, Inc. Modulation of glucagon receptor expression
US20050053981A1 (en) * 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US7626014B2 (en) * 2004-04-27 2009-12-01 Alnylam Pharmaceuticals Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
JP2008513507A (ja) * 2004-09-17 2008-05-01 アイシス ファーマシューティカルズ インコーポレイティッド 増強されたアンチセンスオリゴヌクレオチド
WO2007010628A1 (fr) * 2005-07-22 2007-01-25 Japanese Foundation For Cancer Research Agent prophylactique/thérapeutique pour le cancer
EP1931780B1 (fr) * 2005-08-29 2016-01-06 Regulus Therapeutics Inc. Composes antisens ayant une activite anti-microarn amelioree
WO2007028065A2 (fr) 2005-08-30 2007-03-08 Isis Pharmaceuticals, Inc. Composes oligomeriques chimeriques pour la modulation de l'epissage
BRPI0616158A2 (pt) * 2005-09-19 2011-06-07 Johnson & Johnson Pharmaceutical Res & Dev L L C modulação de expressão de receptor de glucagon
CN101313066A (zh) * 2005-09-19 2008-11-26 强生医药研究及开发有限责任公司 糖皮质激素受体表达的调节
EP2505648A1 (fr) * 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Composés et procédés pour moduler lýexpression de PTP1B
EP2363482A1 (fr) 2006-05-05 2011-09-07 Isis Pharmaceuticals, Inc. Composés et procédés pour moduler l'expression génique
DK2410054T4 (da) * 2006-10-18 2020-02-10 Ionis Pharmaceuticals Inc Antisenseforbindelser
WO2008101157A1 (fr) * 2007-02-15 2008-08-21 Isis Pharmaceuticals, Inc. Nucléosides modifiés 5'-substitués-2'-f et composés oligomères préparés à partir de ceux-ci
EP2167660A1 (fr) * 2007-06-22 2010-03-31 Keygene N.V. Échange nucléotidique ciblé avec des oligonucléotides modifiés améliorés
EP2219680A2 (fr) * 2007-11-13 2010-08-25 Isis Pharmaceuticals, Inc. Composés et méthodes destinées à la modulation de l'expression de protéines
EP2562261B1 (fr) * 2007-12-21 2015-09-09 Keygene N.V. Procédé de mutagenèse amélioré utilisant l'introduction par médiation de polyéthylène glycol de nucléobases mutagènes dans des protoplastes végétaux
RU2572826C2 (ru) 2008-12-02 2016-01-20 Чиралджен, Лтд. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
EP2393825A2 (fr) 2009-02-06 2011-12-14 Isis Pharmaceuticals, Inc. Composés oligomères et procédés connexes
KR20190037378A (ko) 2009-06-17 2019-04-05 바이오젠 엠에이 인코포레이티드 대상에게서 ｓｍｎ２ 스플라이싱을 조정하기 위한 조성물 및 방법
CN102596204B (zh) 2009-07-06 2016-11-23 波涛生命科学有限公司 新的核酸前药及其使用方法
US8276325B2 (en) * 2009-12-31 2012-10-02 The United States Of America As Represented By The Secretary Of The Navy Vehicle and mast mounting assembly therefor
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ 不斉補助基
WO2012109395A1 (fr) 2011-02-08 2012-08-16 Isis Pharmaceuticals, Inc. Composés oligomères comprenant des nucléotides bicycliques et leurs utilisations
US9284343B2 (en) 2011-04-04 2016-03-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides
CA2842358C (fr) 2011-07-19 2020-07-14 Wave Life Sciences Pte. Ltd. Procedes pour la synthese d'acides nucleiques fonctionnalises
US10202599B2 (en) 2011-08-11 2019-02-12 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
JP6092226B2 (ja) 2011-09-20 2017-03-08 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｇｃｇｒ発現のアンチセンス調整
RU2014119787A (ru) 2011-10-25 2015-12-10 Айсис Фармасьютикалс, Инк. Антисмысловая регуляция экспрессии gccr
WO2013159108A2 (fr) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Composés oligomères comprenant des nucléotides bicycliques et utilisations de ceux-ci
KR102450907B1 (ko) 2012-07-13 2022-10-04 웨이브 라이프 사이언시스 리미티드 키랄 제어
JP6246121B2 (ja) 2012-07-13 2017-12-13 株式会社新日本科学 キラル核酸アジュバント
RU2693381C2 (ru) 2012-07-13 2019-07-02 Уэйв Лайф Сайенсес Лтд. Асимметричная вспомогательная группа
EP2906699A4 (fr) 2012-10-11 2016-06-08 Ionis Pharmaceuticals Inc Composés oligomères comportant des nucléosides bicycliques et leurs utilisations
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
US10590412B2 (en) 2013-04-19 2020-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation nucleic acids through nonsense mediated decay
WO2015108046A1 (fr) 2014-01-15 2015-07-23 株式会社新日本科学 Adjuvant d'acide nucléique chiral ayant une activité anti-allergique, et agent anti-allergique
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
EP3095459A4 (fr) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Adjuvant d'acide nucléique chiral ayant un effet antitumoral et agent antitumoral
KR20230152178A (ko) 2014-01-16 2023-11-02 웨이브 라이프 사이언시스 리미티드 키랄 디자인
MA39835A (fr) 2014-04-17 2017-02-22 Biogen Ma Inc Compositions et procédés de modulation de l'épissage du smn2 chez un patient
AU2015329974B2 (en) 2014-10-10 2019-06-20 F. Hoffmann-La Roche Ag GaINAc phosphoramidites, nucleic acid conjugates thereof and their use
DK3234131T3 (da) 2014-12-16 2020-06-29 Roche Innovation Ct Copenhagen As Fremgangsmåde til screening af kiral toksicitet
EP3712269A1 (fr) 2014-12-17 2020-09-23 ProQR Therapeutics II B.V. Édition ciblée d'arn
CN107922946A (zh) 2015-02-04 2018-04-17 霍夫曼-拉罗奇有限公司 Tau反义低聚物及其用途
EP3254104B1 (fr) 2015-02-04 2021-08-25 Bristol-Myers Squibb Company Procédés de sélection de molécules thérapeutiques
LT3386511T (lt) 2015-12-10 2021-08-25 Ptc Therapeutics, Inc. Hantingtono ligos gydymo būdai
JP6985288B2 (ja) 2016-04-14 2021-12-22 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft トリチル−モノ−ＧａｌＮＡｃ化合物とその利用
KR102418185B1 (ko) 2016-06-22 2022-07-06 프로큐알 테라퓨틱스 Ⅱ 비.브이. 단일 가닥 rna-편집 올리고뉴클레오타이드
ES2837076T3 (es) * 2016-09-01 2021-06-29 Proqr Therapeutics Ii Bv Oligonucleótidos para la edición de ARN de cadena sencilla modificados químicamente
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体
US11274300B2 (en) 2017-01-19 2022-03-15 Proqr Therapeutics Ii B.V. Oligonucleotide complexes for use in RNA editing
BR112019025740A2 (pt) 2017-06-05 2020-06-23 Ptc Therapeutics, Inc. Compostos para tratar a doença de huntington
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
BR112020014011A2 (pt) 2018-01-12 2020-12-08 Bristol-Myers Squibb Company Oligonucleotídeos antissenso dirigidos à alfa-sinucleína e usos dos mesmos
BR112020013994A2 (pt) 2018-01-12 2020-12-08 Bristol-Myers Squibb Company Oligonucleotídeos antissenso que direcionam alfa-sinucleína e seus usos
EP3774744B1 (fr) 2018-03-27 2025-02-12 PTC Therapeutics, Inc. Composés pour le traitement de la maladie de huntington
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
CA3103976A1 (fr) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Composes heterocycliques et heteroaryles pour le traitement de la maladie de huntington
CN112805280B (zh) 2018-06-27 2024-12-06 Ptc医疗公司 用于治疗亨廷顿氏病的杂芳基化合物
WO2021084495A1 (fr) 2019-11-01 2021-05-06 Novartis Ag Utilisation d'un modulateur d'épissage pour un traitement ralentissant la progression de la maladie de huntington
TW202304446A (zh) 2021-03-29 2023-02-01 瑞士商諾華公司 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
IL318625A (en) 2022-07-29 2025-03-01 Regeneron Pharma Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle
US20240182561A1 (en) 2022-11-04 2024-06-06 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
WO2024107765A2 (fr) 2022-11-14 2024-05-23 Regeneron Pharmaceuticals, Inc. Compositions et procédés d'administration médiée par le récepteur 3 du facteur de croissance des fibroblastes à des astrocytes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6261840B1 (en) * 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US6369209B1 (en) * 1999-05-03 2002-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6033910A (en) * 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
DE60038220T2 (de) * 1999-08-27 2009-03-12 Novartis Vaccines and Diagnostics, Inc., Emeryville Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon
EP1240322A2 (fr) * 1999-12-23 2002-09-18 Exiqon A/S Utilisations therapeutiques d'oligonucleotides a lna modifie
EP1386004A4 (fr) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc Modulation de l'expression genique associee a la proliferation inflammatoire et a la croissance de neurites, par des procedes faisant intervenir l'acide nucleique
BRPI0313202A8 (pt) * 2002-08-05 2016-08-16 Atugen Ag Formas adicionais para interferir com as moléculas de rna

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6261840B1 (en) * 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FREIER S.M. ET AL.: "The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes", NUCLEIC ACIDS RESEARCH, vol. 25, no. 22, 1997, pages 4429 - 4443, XP003018113 *
KAWASAKI A.M. ET AL.: "Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets", JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 7, 1993, pages 831 - 841, XP000562792 *
POOPEIKO N.E. ET AL.: "Xylo-Configured Oligonucleotides (XNA, Xylo Nucleic Acid): Synthesis of Conformationally Restricted Derivatives and Hybridization Towards DNA and RNA Complements", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 13, February 2003 (2003-02-01), pages 2285 - 2290, XP003018114 *
See also references of EP1670896A4 *

Also Published As

Publication number Publication date
US20090258931A1 (en) 2009-10-15
US20050074801A1 (en) 2005-04-07
EP1670896A2 (fr) 2006-06-21
EP1670896A4 (fr) 2009-03-04
WO2005023995A2 (fr) 2005-03-17
US20140357856A1 (en) 2014-12-04
US8791083B2 (en) 2014-07-29
EP1670896B1 (fr) 2015-01-07

Similar Documents

Publication Publication Date Title
WO2005023995A3 (fr) Composes oligomeres chimeriques comprenant des zones alternees a geometrie conformationnelle nord et sud
WO2001064898A3 (fr) Genes codant pour des enzymes de denitrification
WO2001047944A3 (fr) Acides nucleiques contenant des polymorphismes mononucleotidiques et procedes d'utilisation correspondants
EP2039762A3 (fr) Nitralases
WO2002002809A3 (fr) Diagnostic de troubles du comportement, de troubles neurologiques et de cancers
WO2005042716A3 (fr) Oligonucleotides se liant a des acides nucleiques
WO2003039523A3 (fr) Oligonucleotides modifies a l'aide de nouveaux analogues d'arn-l-alpha
WO2004096842A3 (fr) Sequences de nucleotides et d'acides amines du virus du sras, et utilisations associees
AU2003283839A1 (en) Heteropolyacid and/or its salt supported catalyst, production process of the catalyst and production process of compound using the catalyst
WO2000029623A3 (fr) Acides nucleiques contenant des polymorphismes d'un seul nucleotide et utilisations de ces acides nucleiques
WO2003055913A3 (fr) Proteine secretee
AU2002219137A1 (en) Diagnosis kit, dna chip, and methods for diagnosing or supervising the treatment of testicular cancer
WO1999046375A3 (fr) Sequences d'acide nucleique humaines issues de tissus tumoraux prostatiques
WO2003018629A8 (fr) Antigene cage
AP2388A (en) A group of nucleic acid fragments for prevention of HIV infection or AIDS and the usage thereof.
WO2001012798A3 (fr) Plantes steriles males
WO2002070563A3 (fr) Domaine de liaison de ligand au recepteur hormonal nucleaire
AU2001292326A1 (en) Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like
WO2001051670A3 (fr) Acides nucleiques renfermant des polymorphismes de nucleotide simple et procede d'utilisation associe
WO1999054446A3 (fr) Sequences d'acides nucleiques humains provenant de tissus sains du pancreas
WO2004056983A3 (fr) Proteines de metalloprotease
WO2000029622A3 (fr) Acides nucleiques contenant des polymorphismes d'un nucleotide unique et utilisation de ces acides nucleiques
WO2004070034A3 (fr) Oligonucleotides diriges contre un gene de survivine et utilisation de ceux-ci
WO2003046143A3 (fr) Acides nucleiques contenant des polymorphismes de nucleotides isoles et procedes d'utilisation
AU2002328263A1 (en) Displacement assay for the detection of nucleic acid oligomer hybridization events

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REEP Request for entry into the european phase

Ref document number: 2004788713

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004788713

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004788713

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载